HC Wainwright Reaffirms Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. Several other research analysts also recently commented on ATNM. Cantor Fitzgerald reaffirmed an overweight rating […]

Related Keywords

, Actinium Pharmaceuticals Company Profile , Sanders Morris Harris , News Ratings For Actinium Pharmaceuticals Daily , Maxim Group , Cantor Fitzgerald , Actinium Pharmaceuticals Inc , Creative Financial Designs Inc , Actinium Pharmaceuticals , Vanguard Group Inc , Virtu Financial , Actinium Pharmaceuticals Price Performance , Analyst Recommendations For Actinium Pharmaceuticals , Brandywine Global Investment Management , Free Report , Moderate Buy , Get Free Report , Global Investment Management , Financial Designs , Morris Harris , Actinium Pharmaceuticals Daily ,